<DOC>
	<DOCNO>NCT01495910</DOCNO>
	<brief_summary>The purpose study determine minimum dose abiraterone acetate need decrease serum androstenedione age-appropriate level premenopausal woman steroid replacement classic 21-hydroxylase deficiency .</brief_summary>
	<brief_title>A Study Examining Doses Abiraterone Acetate Adult Women With 21-Hydroxylase Deficiency</brief_title>
	<detailed_description>This non-randomized ( patient assign chance study treatment ) , open-label ( patient know identity study treatment ) , multiple-dose , intra-patient sequential dose-escalation study plan enrollment approximately 10 patient . This study consist screen period treatment period . Due intra-patient dose escalation , multiple treatment period consist 8 day . A rest period least 7 day separate treatment period . Eligible patient take study-defined replacement dose hydrocortisone fludrocortisone . Abiraterone acetate oral suspension administer daily escalate dos 100 mg 500 mg . Patients proceed next high dose level majority treat patient reduction androstenedione level . Serial pharmacokinetic ( study body drug ) pharmacodynamic ( study effect drug body ) sample collect treatment period detail protocol . All patient receive least 1 dose abiraterone acetate analyze safety .</detailed_description>
	<mesh_term>Adrenal Hyperplasia , Congenital</mesh_term>
	<mesh_term>Adrenogenital Syndrome</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Premenopausal woman &gt; =18 year age . Must receive hormonal contraceptive agent contain estrogen progesterone . Confirmed 21hydroxylase deficiency CYP21A2 genotype associate classic congenital adrenal hyperplasia . Demonstrates &gt; =1.5 X ULN morning serum androstenedione concentration take studydefined dos hydrocortisone fludrocortisone . No coexist medical condition opinion investigator would preclude participation study . Current history active chronic hepatitis , include symptomatic viral hepatitis A , B , C. Any active infection . Evidence active malignancy . Serious uncontrolled coexistent nonmalignant disease . Receiving systemic glucocorticoid reason treatment 21hydroxylase deficiency . Any disorder require treatment anticonvulsant . Patients childbearing potential willing use method birth control study 3 month endofstudy . Women pregnant breastfeeding . Genotypes associate nonclassic congenital adrenal hyperplasia .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>21-hydroxylase deficiency</keyword>
	<keyword>Androstenedione</keyword>
	<keyword>Abiraterone acetate</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Dose-finding</keyword>
</DOC>